Pfizer Inc. $PFE Shares Bought by Handelsbanken Fonder AB

Key Points

• Handelsbanken Fonder AB increased its Pfizer position by 10.4% in the second quarter, acquiring 232,528 additional shares for a total holding of 2.46 million shares valued at approximately $59.3 million.
• Analysts maintain a broadly cautious outlook, with a consensus “Hold” rating and a $28.28 price target. Pfizer shares opened at $27.04, within their 52-week range of $23.58 to $28.75.
• Pfizer beat quarterly expectations, reporting $0.77 in EPS versus the $0.68 consensus and $15.03 billion in revenue. The company also declared a quarterly dividend of $0.43 per share, equivalent to a 6.4% annualized yield.

Handelsbanken Fonder AB raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 10.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,462,431 shares of the biopharmaceutical company's stock after purchasing an additional 232,528 shares during the period. Handelsbanken Fonder AB's holdings in Pfizer were worth $59,295,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Godfrey Financial Associates Inc. acquired a new position in Pfizer during the fourth quarter worth approximately $26,000. HFM Investment Advisors LLC boosted its holdings in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 427 shares during the last quarter. Evolution Wealth Management Inc. boosted its holdings in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 566 shares during the last quarter. Abound Financial LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $31,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on PFE shares. Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. UBS Group reaffirmed a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. Weiss Ratings reiterated a "hold (c)" rating on shares of Pfizer in a report on Monday, August 3rd. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $28.28.

Pfizer Trading Up 1.0%

NYSE PFE opened at $27.04 on Tuesday. The stock has a market cap of $154.12 billion, a P/E ratio of 35.58 and a beta of 0.34. The company's fifty day simple moving average is $25.05 and its 200-day simple moving average is $26.18. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the business earned $0.78 EPS. The business's revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer Inc. will post 2.97 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer's payout ratio is presently 226.32%.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source